natgillin/translations-raw huggingface dataset:
If the potential benefit of reinitiating pazopanib treatment is considered to outweigh the risk for hepatotoxicity, then reintroduce pazopanib at a reduced dose of 400 mg daily and perform serum liver tests weekly for 8 weeks. 
Če je pričakovana korist ponovne uvedbe zdravljenja s pazopanibom večja od tveganja za pojav hepatotoksičnih učinkov, je treba uvesti zdravljenje s pazopanibom z nižjim odmerkom 400 mg na dan in opravljati serumske jetrne teste vsak teden 8 tednov.
It is not yet known how well it works in this age group. 
V tej starostni skupini delovanje zdravila še ni popolnoma znano.
Tell your doctor if you notice significant weight gain or tiredness. 
Obvestite zdravnika, če opazite znatno povečanje telesne mase ali utrujenost.
Daily dosing results in 1.23- to 4-fold increase in AUC0-T. 
Pri dnevnem odmerjanju se vrednost AUC0-T poveča za 1,23-krat do 4-krat.
For patients who responded to treatment, the median time to response was 11.9 weeks and the median duration of response was 58.7 weeks as per independent review (VEG105192). 
Neodvisna presoja je pokazala, da je bila pri bolnikih, ki so se odzvali na zdravljenje, mediana vrednost časa do odziva 11,9 tedna, mediana vrednost trajanja odziva pa 58,7 tedna (VEG105192).
Laboratory abnormalities were reported as adverse events less frequently by investigators than as indicated by laboratory value tables. 
Laboratorijske nepravilnosti so kot neželene učinke raziskovalci opisali manj pogosto, kot kažejo preglednice laboratorijskih vrednosti.
Effect of concomitant use of pazopanib and simvastatin 
Vpliv sočasne uporabe pazopaniba in simvastatina
Liver function should be monitored in all subjects receiving pazopanib, regardless of genotype or age (see section 5.1). 
Delovanje jeter je treba spremljati pri vseh osebah, ki prejemajo pazopanib, ne glede na njihov genotip in starost (glejte poglavje 5.1).
Effects of pazopanib on other medicinal products 
Vpliv pazopaniba na druga zdravila
There are limited data on the use of pazopanib in patients aged 65 years and older. 
Podatkov o uporabi pazopaniba pri bolnikih, starih 65 let in starejših, je malo.
The following tumour types were not eligible: 
Neprimerni so bili naslednji tipi tumorjev:
Synovial sarcoma subgroups* N = 25 
Podskupine sinovijskega sarkoma n = 25
Infections occurring while you take Votrient may possibly become serious. 
Okužbe, ki se pojavijo v času jemanja zdravila Votrient, se lahko razvijejo v resne okužbe.
Concomitant use of pazopanib and simvastatin increases the risk of ALT elevations (see section 4.5) and should be undertaken with caution and close monitoring. 
Sočasna uporaba pazopaniba in simvastatina poveča tveganje za zvišanje ALT (glejte poglavje 4.5), zato je treba to kombinacijo uporabljati previdno in ob natančnem nadzoru.
PRES/RPLS can present with headache, hypertension, seizure, lethargy, confusion, blindness and other visual and neurological disturbances, and can be fatal. 
PRES/RPLS se lahko pokaže z glavobolom, hipertenzijo, konvulzijami, letargijo, zmedenostjo, slepoto in drugimi motnjami vida oziroma nevrološkimi motnjami ter se lahko konča smrtno.
Pazopanib should not be used during pregnancy unless the clinical condition of the woman requires treatment with pazopanib. 
Pazopaniba se med nosečnostjo ne sme uporabljati, razen če klinično stanje bolnice zahteva zdravljenje s pazopanibom.
Decreased appetite and anorexia f Cardiac dysfunction, left ventricular dysfunction, cardiac failure and restrictive cardiomyopathy g 
Zmanjšan apetit in neješčnost (anoreksija) f Disfunkcija srca, disfunkcija levega prekata, srčno popuščanje in restriktivna kardiomiopatija g
It should be taken without food, at least one hour before or two hours after a meal (see section 5.2). 
Jemati ga je treba brez hrane, vsaj eno uro pred ali dve uri po jedi (glejte poglavje 5.2).
Patients were stratified by the factors of WHO performance status (WHO PS) (0 or 1) at baseline and the number of lines of prior systemic therapy for advanced disease (0 or 1 vs. 2+). 
Bolnike so stratificirali po faktorjih stanja zmogljivosti po Svetovni zdravstveni organizaciji (WHO PS) (0 ali 1) izhodiščno in po številu linij predhodnega sistemskega zdravljenja za napredovalo bolezen (0 ali 1 v prim.
The type of medicine that you are taking to reduce your stomach acid (e.g. proton pump inhibitor, H2 antagonists or antacids) may affect how Votrient is taken. 
Določena vrsta zdravil, ki se uporabljajo za zmanjšanje želodčne kisline (npr. zaviralci protonske črpalke, antagonisti H2 ali antacidi) lahko vplivajo na to, kako se jemlje zdravilo Votrient.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) 
Benigne, maligne in neopredeljene neoplazme (vključno s cistami in polipi)
PFS Overall Median (months) (95% CI) 
PFS Skupaj Mediana (meseci) (95 % IZ)
Median (months) 
Mediana (meseci)
Other observed effects include body weight loss, diarrhoea and/or morbidity that were either secondary to local gastrointestinal effects caused by high local mucosal medicinal product exposure (monkeys) or pharmacological effects (rodents). 
Drugi opaženi učinki so bili: zmanjšanje telesne mase, driska in/ali morbidnosti, ki so bile bodisi sekundarnega porekla zaradi lokalnih gastrointestinalnih učinkov, povzročenih z visoko lokalno izpostavljenostjo sluznice zdravilu (opice) ali farmakoloških učinkov (glodavci).
Pazopanib should be discontinued if there is evidence of hypertensive crisis or if hypertension is severe and persists despite anti-hypertensive therapy and pazopanib dose reduction. 
Zdravljenje s pazopanibom je treba ukiniti v primeru hipertenzivne krize ali če je hipertenzija huda in traja kljub antihipertenzivnemu zdravljenju in znižanju odmerka pazopaniba.
In clinical studies with pazopanib, events of hypertension including newly diagnosed symptomatic episodes of elevated blood pressure (hypertensive crisis) have occurred. 
V kliničnih študijah s pazopanibom so se pojavili primeri hipertenzije, vključno z na novo diagnosticiranimi simptomatskimi epizodami zvišanega krvnega tlaka (hipertenzivna kriza).
In VEG108844, patients (N = 1110) with locally advanced and/or metastatic RCC who had not received prior systemic therapy, were randomised to receive either pazopanib 800 mg once daily continuously or sunitinib 50 mg once daily in 6-week cycles of dosing with 4 weeks on treatment followed by 2 weeks without treatment. 
V VEG108844 so bolnike (N = 1110) z lokalno napredovalim in/ali metastatskim RCC, ki predhodno niso prejemali sistemskega zdravljenja, randomizirali na prejemanje ali pazopaniba 800 mg enkrat na dan neprekinjeno ali sunitiniba 50 mg enkrat na dan v 6-tedenskih ciklusih, ki so obsegali 4 tedne zdravljenja in 2 tedna brez zdravljenja.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, tudi če ste ga dobili brez recepta, vključno z zdravili rastlinskega izvora.
Overall Survival Median (months) (95% CI) 
Celokupno preživetje Mediana (meseci) (95 % IZ)
The 200 mg tablets also contain iron oxide red (E172). 
200 mg filmsko obložene tablete vsebujejo tudi rdeči železov oksid (E172).
g Cardiac dysfunction events - includes Left ventricular dysfunction, Cardiac failure and Restrictive cardiomyopathy h Frequency is based on adverse events reported by investigators. 
g Dogodki motenega delovanja srca - vključuje moteno delovanje levega prekata, srčno popuščanje in restriktivno kardiomiopatijo h Pogostnost temelji na neželenih učinkih, o katerih so poročali raziskovalci.
The decision to resume pazopanib after surgery should be based on clinical judgement of adequate wound healing. 
Odločitev o nadaljevanju zdravljenja s pazopanibom po opravljenem kirurškem posegu je treba sprejeti na osnovi klinične presoje ustreznosti celjenja rane.
Effects included reduced female fertility, increased pre- and post-implantation loss, early resorptions, embryo lethality, decreased foetal body weight and cardiovascular malformation. 
Učinki so obsegali, zmanjšano plodnost samic, pogostejše izgube pred in po nidaciji, zgodnje resorpcije, smrtnost zarodkov, zmanjšano telesno maso zarodkov in kardiovaskularne malformacije.
Binding of pazopanib to human plasma protein in vivo was greater than 99% with no concentration dependence over the range of 10-100 g/ml. 
Vezava pazopaniba na humane plazemske proteine je in vivo večja od 99 % in v razponu od 10100 g/ml ni odvisna od koncentracije.
Don't stop Votrient without advice Take Votrient for as long as your doctor recommends. 
Zdravila Votrient ne smete nehati jemati brez nasveta zdravnika Zdravilo Votrient morate jemati tako dolgo, kot vam je to predpisal zdravnik.
The following tumour types were eligible: 
Primerni so bili naslednji tipi tumorjev:
Posterior reversible encephalopathy syndrome (PRES)/Reversible posterior leukoencephalopathy syndrome (RPLS) 
Sindrom posteriorne reverzibilne encefalopatije (PRES - Posterior reversible encephalopathy syndrome)/reverzibilni posteriorni levkoencefalopatski sindrom (RPLS - Reversible posterior leukoencephalopathy syndrome)
In vitro studies with human liver microsomes showed that pazopanib inhibited CYP enzymes 1A2, 3A4, 2B6, 2C8, 2C9, 2C19, and 2E1. 
Študije in vitro s humanimi jetrnimi mikrosomi so pokazale, da pazopanib zavira encime CYP 1A2, 3A4, 2B6, 2C8, 2C9, 2C19 in 2E1.
Tabulated list of adverse reactions 
Tabelirani seznam neželenih učinkov
Disease characteristics at initial diagnosis and at screening were balanced between the treatment arms with the majority of patients having clear cell histology and Stage IV disease. 
Značilnosti bolezni ob uvodni diagnozi in ob presejanju so bile med terapevtskima skupinama uravnotežene; večina bolnikov je imela svetlocelično histologijo in bolezen v IV. stadiju.
Clinical pharmacology studies, using pazopanib 800 mg once daily, have demonstrated that pazopanib does not have a clinically relevant effect on the pharmacokinetics of caffeine (CYP1A2 probe substrate), warfarin (CYP2C9 probe substrate), or omeprazole (CYP2C19 probe substrate) in cancer patients. 
Klinične farmakološke študije z uporabo pazopaniba v odmerku 800 mg enkrat na dan so pokazale, da pazopanib pri bolnikih z rakom nima klinično pomembnih učinkov na farmakokinetiko kofeina (preiskovani substrat za CYP1A2), varfarina (preiskovani substrat za CYP2C9) ali omeprazola (preiskovani substrat za CYP2C19).
Investigated dose 
Raziskovani odmerek
One of these metabolites inhibits the proliferation of VEGF-stimulated human umbilical vein endothelial cells with a similar potency to that of pazopanib, the others are 10- to 20-fold less active. 
Eden od teh presnovkov zavira z žilnim endotelijskim rastnim faktorjem (VEGF) stimulirano proliferacijo humanih endotelnih celic umbilikalne vene z enako jakostjo kot pazopanib, ostali pa so za od 10- do 20-krat manj aktivni.
The median duration of follow-up of subjects (defined as date of randomisation to date of last contact or death) was similar for both treatment arms (9.36 months for placebo [range 0.69 to 23.0 months] and 10.04 months for pazopanib [range 0.2 to 24.3 months]. 
Mediano trajanje spremljanja preiskovancev (opredeljeno kot obdobje od datuma randomizacije do datuma zadnjega stika ali smrti) je bilo v obeh terapevtskih skupinah podobno (9,36 meseca za placebo [razpon od 0,69 do 23,0 meseca] in 10,04 meseca za pazopanib [razpon od 0,2 do 24,3 meseca]).
These were reported as adverse events less frequently by investigators than as indicated by laboratory value tables. 
Raziskovalci so te neželene učinke opisali manj pogosto, kot kažejo preglednice laboratorijskih vrednosti.
You must look out for certain symptoms while you are taking Votrient to reduce the risk of any problems. 
Med zdravljenjem z zdravilom Votrient morate biti še posebej pozorni na nekatere simptome, da bi se tako zmanjšalo tveganje za pojav kakršnih koli resnejših težav.
Results from population pharmacokinetic modelling (data from subjects with baseline CLCR values ranging from 30.8 ml/min to 150 ml/min) indicated that renal impairment is unlikely to have clinically relevant effect on pazopanib pharmacokinetics. 
Rezultati populacijskega farmakokinetičnega modeliranja (podatki od oseb z izhodiščno vrednostjo kreatininskega očistka v razponu od 30,8 ml/min do 150 ml/min) kažejo, da je malo verjetno, da bi okvara ledvic imela klinično pomemben učinek na farmakokinetiko pazopaniba.
Effects of other medicinal products on pazopanib 
Vpliv drugih zdravil na pazopanib
Neutropenia, thrombocytopenia and palmar-plantar erythrodysaethesia syndrome were observed more frequently in patients of East Asian descent. 
Nevtropenijo, trombocitopenijo in sindrom palmarno-plantarne eritrodizestezije so pogosteje opažali pri bolnikih vzhodnoazijskega porekla.
Soft-tissue sarcoma (STS) 
Sarkom mehkih tkiv (STS)
Outcome 
Izid
Because the mechanism of action of pazopanib can severely affect organ growth and maturation during early post-natal development in rodents (see section 5.3), pazopanib should not be given to paediatric patients younger than 2 years of age. 
Mehanizem delovanja pazopaniba lahko pri glodalcih hudo prizadene rast in dozorevanje organov med zgodnjim postnatalnim obdobjem (glejte poglavje 5.3), zato se pazopaniba ne sme uporabljati pri pediatričnih bolnikih, mlajših od 2 let.
CYP3A4, P-gp, BCRP inducers 
Induktorji CYP3A4, P-gp, BCRP
Dosing recommendations in hepatically impaired patients are based on pharmacokinetic studies of pazopanib in patients with varying degrees of hepatic dysfunction (see section 5.2). 
Priporočila za odmerjanje pri bolnikih z okvaro jeter temeljijo na farmakokinetičnih študijah pazopaniba pri bolnikih z različnimi stopnjami motenega delovanja jeter (glejte poglavje 5.2).
Baseline and periodic urinanalysis during treatment is recommended and patients should be monitored for worsening proteinuria. 
Pred začetkom zdravljenja in periodično med zdravljenjem je priporočljivo opraviti preiskave urina, bolnike pa je treba nadzirati glede poslabšanja proteinurije.
Patients should be carefully monitored for clinical signs or symptoms of congestive heart failure. 
Bolnike je treba natančno kontrolirati glede kliničnih znakov ali simptomov kongestivnega srčnega popuščanja.
- The other ingredients in the 200 mg and 400 mg tablets are: hypromellose, macrogol 400, magnesium stearate, microcrystalline cellulose, polysorbate 80, povidone (K30), sodium starch glycolate, titanium dioxide (E171). 
- Druge sestavine 200 mg in 400 mg filmsko obloženih tablet so: hipromeloza, makrogol 400, magnezijev stearat, mikrokristalna celuloza, polisorbat 80, povidon (K30), natrijev karboksimetilškrob in titanov dioksid (E171).
Potential induction of human CYP3A4 was demonstrated in an in vitro human PXR assay. 
Morebitna indukcija CYP3A4 je pri človeku bila dokazana in vitro s humanim PXR.
Symptoms include: - loss of speech - change of vision - seizure (fits) - confusion - high blood pressure 
Med simptomi so: - izguba govora, - sprememba vida, - konvulzije (napadi krčev), - zmedenost, - visok krvni tlak.
Don't take Votrient with food. 
Ne jemljite zdravila Votrient skupaj s hrano.
Votrient may cause blood clots in the small blood vessels in the kidneys and brain accompanied by a decrease in red blood cells and cells involved in clotting (thrombotic microangiopathy, TMA). 
Zdravilo Votrient lahko povzroči nastanek krvnih strdkov v majhnih krvnih žilah ledvic in možganov, ki jih spremlja zmanjšanje števila rdečih krvnih celic in celic, ki sodelujejo pri strjevanju krvi (trombotična mikroangiopatija).
Votrient treatment should only be initiated by a physician experienced in the administration of anti-cancer medicinal products. 
Zdravljenje z zdravilom Votrient sme uvesti le zdravnik, ki ima izkušnje z uporabo protitumorskih zdravil.
‘Other STS' subgroups 
Podskupina "drugi STS"
This can result in weight increase and tiredness. 
To lahko povzroči povečanje telesne mase in utrujenost.
Adverse drug reactions, all grades, which were reported in RCC and STS subjects or during the post-marketing period are listed below by MedDRA body system organ class, frequency and grade of severity. 
Neželeni učinki zdravila (vseh stopenj), o katerih so poročali pri preiskovancih z RCC in STS ali v obdobju po prihodu zdravila na trg, so v nadaljevanju navedeni po MedDRA podatkovni bazi glede na organske sisteme, pogostnosti in stopnjo resnosti.
Patients with only a mild indirect hyperbilirubinaemia, known or suspected Gilbert's syndrome, and elevation in ALT >3 x ULN should be managed as per the recommendations outlined for isolated ALT elevations. 
Bolnike z le blago indirektno hiperbilirubinemijo ali znanim Gilbertovim sindromom ali sumom nanj ter z ALT > 3-kratno ZMN je treba obravnavati po priporočilih, opisanih za primer izoliranega zvišanja ALT.
†Treatment-related adverse reaction reported during post-marketing period (spontaneous case reports and serious adverse reactions from all pazopanib clinical studies). 
† Z zdravljenjem povezani neželeni učinki, o katerih so poročali v obdobju trženja (spontano prijavljeni primeri in resni neželeni učinki iz vseh kliničnih študij s pazopanibom).
Swelling of the brain (reversible posterior leukoencephalopathy syndrome) Votrient can, on rare occasions, cause swelling of the brain, which may be life threatening. 
Oteklost možganov (reverzibilni posteriorni levkoencefalopatski sindrom) Zdravilo Votrient lahko v redkih primerih povzroči otekanje možganov, ki je lahko smrtno nevarno.
Medicinal products that raise gastric pH 
Zdravila, ki zvišujejo pH v želodcu
“Other STS” subgroups* 
Podskupine "drugi STS"*
Interstitial lung disease (ILD)/Pneumonitis 
Intersticijska bolezen pljuč (IBP)/pnevmonitis
If you have high blood pressure you will be treated with medicines to reduce it. 
Če imate visok krvni tlak, vam bo zdravnik predpisal zdravila za zdravljenje visokega krvnega tlaka.
The safety, efficacy and quality of life of pazopanib versus sunitinib was evaluated in a randomised, open-label, parallel group Phase III non-inferiority study (VEG108844). 
Varnost, učinkovitost in kakovost življenja s pazopanibom v primerjavi s sunitinibom so ocenili v randomizirani, odprti študiji neinferiornosti faze III z vzporednimi skupinami (VEG108844).
In vitro, pazopanib inhibited human organic anion transporting polypeptide (OATP1B1). 
In vitro je pazopanib zavrl humani transportni polipeptid za organske anione (OATP1B1).
Votrient can, on rare occasions, cause lung inflammation (interstitial lung disease, pneumonitis), which in some people can be fatal. 
Zdravilo Votrient lahko v redkih primerih povzroči vnetje pljuč (intersticijsko bolezen pljuč, pnevmonitis), ki je lahko za nekatere bolnike smrtno.
Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, protein kinase inhibitors, ATC code: L01XE11 
Farmakoterapevtska skupina: Zdravila z delovanjem na novotvorbe, druga zdravila z delovanjem na novotvorbe, zaviralci proteinskih kinaz, oznaka ATC: L01XE11
Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. 
Zdravilo Votrient je indicirano za zdravljenje odraslih bolnikov z določenimi podvrstami napredovalega sarkoma mehkih tkiv (STS - soft tissue sarcoma), ki so predhodno prejemali kemoterapijo zaradi metastatske bolezni ali jim je bolezen napredovala v 12 mesecih po (neo)adjuvantnem zdravljenju.
Possible serious side effects 
Možni resni neželeni učinki
Hypertensive crisis (sudden and severe rise in blood pressure) Votrient can on occasion cause a sudden and severe rise in blood pressure. 
Hipertenzivna kriza (nenaden porast krvnega tlaka na zelo visoke vrednosti) Zdravilo Votrient lahko občasno povzroči nenaden porast krvnega tlaka na zelo visoke vrednosti.
Pazopanib should be used with caution in patients who are at increased risk of thrombotic events or who have had a history of thrombotic events. 
Pazopanib je treba previdno uporabljati pri bolnikih, ki imajo večje tveganje za trombotične dogodke ali imajo trombotične dogodke v anamnezi.
These results indicate that the bioavailability and the rate of pazopanib oral absorption are increased after administration of the crushed tablet relative to administration of the whole tablet (see section 4.2). 
Ti rezultati kažejo, da se biološka uporabnost in stopnja absorpcije pazopaniba pri peroralni uporabi zdrobljene tablete v primerjavi z uporabo cele tablete poveča (glejte poglavje 4.2).
In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in various animal models, and the growth of multiple human tumour xenografts in mice. 
In vivo je pazopanib zaviral z žilnim endotelijskim rastnim faktorjem povzročeno fosforilacijo VEGFR-2 v pljučih miši, angiogenezo pri različnih živalskih modelih in rast multiplih humanih tumorskih ksenogenskih presadkov pri miših.
Votrient can lower the amount of thyroid hormone produced in your body. 
Zdravilo Votrient lahko zmanjša tvorbo ščitničnih hormonov v telesu.
Patients (N = 435) with locally advanced and/or metastatic RCC were randomised to receive pazopanib 800 mg once daily or placebo. 
Bolniki (n = 435) z lokalno napredovalim in/ali metastatskim RCC so bili randomizirani tako, da so prejemali pazopanib v odmerku 800 mg enkrat na dan ali placebo.
The usual dose is two Votrient 400 mg tablets (800 mg pazopanib) taken once a day. 
Običajen odmerek sta dve 400 mg tableti zdravila Votrient (800 mg pazopaniba) enkrat na dan.
It is not known whether the ingredients in Votrient pass into breast milk. 
Ni znano, če se sestavine zdravila Votrient izločajo z materinim mlekom.
Votrient can make some conditions worse or cause serious side effects. 
Zdravilo Votrient lahko poslabša nekatera zdravstvena stanja ali povzroči resne neželene učinke.
CYP3A4, P-gp, BCRP inhibitors Pazopanib is a substrate for CYP3A4, P-gp and BCRP. 
Zaviralci CYP3A4, P-gp, BCRP Pazopanib je substrat CYP3A4, P-gp in BCRP.
Human paediatric patients are at increased risk for bone and teeth effects as compared to adults, as these changes, including inhibition of growth (shortened limbs), fragile bones and remodelling of teeth, were present in juvenile rats at ≥10 mg/kg/day (equal to approximately 0.1-0.2 times the clinical exposure based on AUC in adult humans) (see section 4.4). 
Pri človeku obstaja pri pediatričnih bolnikih večje tveganje za učinke na kosti in zobe kot pri odraslih: te spremembe - vključno z zavrtjem rasti (krajši udi), krhkimi kostmi in remodeliranjem zob - so bile pri mladih podganah prisotne pri ≥ 10 mg/kg/dan (to je približno 0,1- do 0,2-kratnik klinične izpostavljenosti na podlagi AUC pri odraslih ljudeh) (glejte poglavje 4.4).
Upon oral administration of a single pazopanib 800 mg dose to patients with solid tumours, maximum plasma concentration (Cmax) of approximately 19 ± 13 µg/ml was obtained after median 3.5 hours (range 1.0-11.9 hours) and an AUC0-∞ of approximately 650 ± 500 µg.h/ml was obtained. 
Po peroralni uporabi enkratnega 800 mg odmerka pazopaniba je bila pri bolnikih s solidnim tumorjem dosežena največja plazemska koncentracija (Cmax) približno 19 ± 13 µg/ml po mediani vrednosti 3,5 ure (razpon od 1,0 do 11,9 ur) in dosežena vrednost AUC0-∞ približno 650 ± 500 µg.h/ml.
It cannot be excluded that pazopanib will affect the pharmacokinetics of substrates of OATP1B1 (e.g. statins, see “Effect of concomitant use of pazopanib and simvastatin” below). 
Vpliva pazopaniba na farmakokinetiko substratov OATP1B1 (npr. statinov, glejte ''Vpliv sočasne uporabe pazopaniba in simvastatina” spodaj) ni mogoče izključiti.
In the RCC studies of pazopanib, overall no clinically significant differences in safety of pazopanib were observed between subjects aged at least 65 years and younger subjects. 
V kliničnih študijah RCC, izvedenih s pazopanibom, se varnost uporabe pazopaniba pri bolnikih, starih vsaj 65 let, v celoti klinično ni pomembneje razlikovala od varnosti pri mlajših bolnikih.